Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Zhou, Pei-Yun; Tang, Zheng; Liu, Wei-Ren; Tian, Meng-Xin; Jin, Lei; Jiang, Xi-Fei; Wang, Han; Tao, Chen-Yang; Ding, Zhen-Bin; Peng, Yuan-Fei; Qiu, Shuang-Jian; Dai, Zhi; Zhou, Jian; Fan, Jia; Shi, Ying-Hong

doi:10.1186/s12885-017-3745-z

Table 3 Demographics and clinical characteristics of 215 patients after PSM

From: Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Characteristic	Variable	After PSM
		No-PBT	PBT	P value
		(n = 163)	(n = 52)	P value
Age	Y ± SD	57.67 ± 10.77	56.90 ± 12.34	0.114^a
Gender	female/male	72/91	27/25	0.330^c
Preoperative Hb	g/L ± SD	125.38 ± 15.90	120.25 ± 18.72	0.232^a
Platelet	1 × 10⁹/L ± SD	180.29 ± 65.50	193.38 ± 93.35	0.350^a
Total bilirubin	umol/L ± SD	31.34 ± 62.77	60.36 ± 115.37	0.070^b
AST	available data	161 (98.77%)	50 (96.15%)
AST	U/L ± SD	46.25 ± 81.74	47.92 ± 62.24	0.763^b
ALT	U/L ± SD	51.14 ± 80.64	53.35 ± 77.74	0.374^b
AFP	available data	158 (96.93%)	52 (100.00%)
AFP	ng/mL ± SD	196.77 ± 1590.50	123.49 ± 741.51	0.994^b
CEA	available data	157 (96.32%)	49 (94.23%)
CEA	ng/mL ± SD	22.66 ± 149.81	95.03 ± 437.78	0.375^b
CA19–9	available data	156 (95.71%)	48 (92.31%)
CA19–9	U/mL ± SD	1170.62 ± 3041.71	1491.47 ± 3691.9	0.439^b
PT	available data	161 (98.77%)	51 (98.08%)
PT	s ± SD	10.76 ± 4.65	11.96 ± 3.59	0.075^b
INR	available data	158 (96.93%)	50 (96.15%)
	Value ±SD	0.98 ± 0.13	0.98 ± 0.15	0.997^b
HBsAg	available data	160 (98.16%)	52 (100.00%)
HBsAg	(−)/(+)	100/60	39/13	0.100^c
Anti-HCV	available data	159 (97.55%)	52 (100.00%)
Anti-HCV	(−)/(+)	157/2	51/1	0.726^c
Tumor number	1/>1	140/23	43/9	0.574^c
TMD	cm	6.84 ± 3.39	6.83 ± 3.38	0.967^c
TNM stage	available data	155(95.09%)	44 (84.62%)
TNM stage	I/II/III/IVa	92/24/5/34	25/11/0/8	0.968^c
Cirrhotic nodule	available data	163 (100%)	50 (96.2%)
Cirrhotic nodule	no/yes	112/51	40/10	0.123^c
DD	available data	126 (77.30%)	43 (82.70%)
DD	I/ II-III	2/124 (1.59%)	0/43 (0.00%)	0.407^c
IBL	<1 L/≥1 L	161/2 (98.77%)	52/0 (100.00%)	0.423^c
Preventive TACE	no/yes	153/10 (93.87%)	47/5 (90.38%)	0.392^c
Propensity Score		0.136 ± 0.117	0.193 ± 0.167	0.785^d

^at test
^bK-Independent-Samples Test (Kruskal Wallis H(K) test)
^cTwo-Independent-Samples Test (Mann-Whitney U test)
^dTwo-Related-Samples Test (Wilcoxon Signed Ranks Test)
Values are presented as n (%) or mean ± standard deviation

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us